Anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is reported to induce EGFR internalization in colorectal cancer (CRC) cells. However, the biological relevance of EGFR internalization with anti-EGFR mAb is unknown. Therefore, the relevance of EGFR downregulation with anti-EGFR mAb to anti-tumor activity in CRC cells was investigated. Quantification of EGFR on the cell surface before cetuximab treatment was assessed by flow cytometry, and its growth-inhibitory effects were measured by trypan blue-exclusion, in 10 RAS, BRAF wild-type CRC cell lines, but there was no significant correlation between EGFR number and its growth-inhibitory effect. However, a significant correlation existed between the percentage decrease in the number of EGFRs after cetuximab treatment and its growth-inhibitory effect in those cell lines. Treatment with TGF-α, a ligand for EGFR, induced EGFR internalization in CRC cells, but most EGFRs subsequently recycled to the cell surface, consistent with previous studies. While cetuximab treatment induced EGFR internalization, most receptors subsequently translocated into the late endosome, leading to lysosomal degradation, as revealed by immunoblotting and double immunofluorescence. Cetuximab-sensitive CRC cells showed greater EGFR internalization, stronger cell growth inhibition, and more augmented apoptotic signals than non-sensitive cells.
Introduction
Epidermal growth factor receptor (EGFR) represents a unique target in cancer therapy because overexpression of EGFRs has been implicated in the pathogenesis of many malignant tumors, such as head and neck cancer, colorectal cancer (CRC), lung cancer, ovarian cancer, cervical cancer, and gastric cancer (1) (2) (3) (4) (5) (6) . There are two therapeutic strategies targeting EGFRs: monoclonal antibodies (mAbs) and tyrosine kinase inhibitors against EGFR.
While kinase inhibitors bind to the intracellular domain of the EGFR and block kinase activity, antibodies target the extracellular part of the receptor, thereby preventing ligand binding, conformational activation, and/or receptor dimerization (7) (8) (9) . For patients with metastatic CRC (mCRC), two mAbs targeting EGFR, cetuximab and panitumumab, have been proven to be effective in combination with chemotherapy or as monotherapy (10) (11) (12) (13) (14) (15) . However, recently it has been shown that these drugs are ineffective in CRCs with RAS mutation, which causes constant oncogenic activation of RAS/MEK/ERK signal transduction at the EGFR downstream. Thus, RAS mutation is the only established biomarker for selection of patients with mCRC. Moreover, numerous studies have investigated the association of EGFR molecular events with the response to EGFR mAbs and have demonstrated that the levels of expression or somatic mutations of EGFR did not correlate with clinical responses to cetuximab and panitumumab. Thus, the response to EGFR mAbs varies among individuals 7 and cannot be universally expected even in the RAS wild-type mCRC, which presents a significant problem in clinical practice.
Anti-EGFR mAbs bind to domain III of the EGFR and inhibit binding of activating ligands (16) . They also have a cytotoxic effect by inducing antibody-dependent cellular cytotoxicity (ADCC) and can counteract tumor growth through several different mechanisms (17) . One important mechanism to counteract cancer cell proliferation is induction of receptor internalization and downregulation. The mouse anti-EGFR mAb (clone 225) has been shown to induce endocytosis of the EGFR (18, 19) . However, antibody-dependent EGFR dynamics are very complex, and the mechanism and pattern of cetuximab-induced downregulation of EGFR in CRC is not fully understood. Moreover, it is unclear whether antibody-induced EGFR internalization is related to the antibody's biological activity. Therefore, we have in the current study investigated how antibody-induced EGFR downregulation is associated with anti-tumor activity in CRC cells. Our results suggest that the degree of EGFR degradation is a more important determinant of cetuximab treatment efficacy than the initial number of EGFRs on the cell surface. Furthermore, we demonstrated that cetuximab binding to EGFR augments EGFR downregulation due to its translocalization to the late endosome, leading to lysosomal degradation. These studies provide new clinical insight into the mechanism of responsiveness to anti-EGFR antibody therapy. 
Materials and Methods

Cell culture and reagents
We used 22 No specific authentication of the M7609 cell line was performed. All cell lines were cultured in recommended media supplemented with fetal bovine serum (FBS) at 37 °C with CO 2 , as described in Supplementary Table S1 . Cetuximab was purchased from Merck Co., Ltd.
(Darmstadt, Germany). A recombinant human epidermal growth factor (EGF) was obtained from Pepro Tech Inc. (Rocky Hill, NJ). Recombinant human transforming growth factor-α (TGF-α) and amphiregulin were obtained from Wako Co., Ltd. (Tokyo, Japan). 
Mutational analyses of KRAS, NRAS, BRAF, PIK3CA, and EGFR
Genomic DNA was extracted from each cell line using a QIAamp Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. KRAS (codon 12, 13) and BRAF (codon 600) and EGFR ectodomain (exon 12) mutations were detected by direct sequencing using an ABI PRISM ® 3100 Genetic Analyzer (Applied Biosystems, Hitachi, Japan). Mutations in KRAS (codons 61, 146), NRAS (codons 12, 13, 61), and PIK3CA (codon 1047) were detected by Luminex assay. We excluded PIK3CA codon 542, 545, and 546 mutational analysis because it has already been shown that they have no significant effect on the response to cetuximab treatment (20) . Mutations in the intracellular domain of EGFR were detected by the peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp method (21, 22) . This technique detects several EGFR mutations including G719S, G719C, G719A, T790M, L858R, L861Q, and exon 19 deletions.
Cell viability assay
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Cell viability was determined using the trypan blue dye exclusion method. Each cell line (1.0 × 10 5 cells) was plated in a 6-well plate and incubated in medium with 10% FBS in the presence of cetuximab (30 nM) or vehicle only. Viable cells were counted at day 4 and day 7 using a Countess II automated cell counter (Thermo Fisher Scientific, Inc., Waltham, MA).
The growth inhibition rate was calculated as the ratio of the cell number in the presence of cetuximab to that in the presence of vehicle only.
Quantification of cell surface EGFR by flow cytometry
Cells were washed and then detached using trypsin and EDTA at 37 °C. streptavidin-agarose beads, and subjected to Western blot analyses.
Double immunofluorescence
Cells were fixed with 4% paraformaldehyde for 30 minutes and permeabilized with 0.25% Triton X-100 in PBS for 5 minutes. After blocking using 5% BSA in PBS with 0.03%
Triton X-100 for 1 hour at room temperature, the cells were incubated with anti-EGFR Alexa 
Patients
Thirteen patients with CRC whose tissues were available before and after anti-EGFR mAb treatment by surgical resection or endoscopic biopsies were enrolled. Baseline characteristics of the patients are shown in Table 1 
Immunohistochemistry (IHC)
Immunohistochemical staining for EGFR in CRC tissue was performed using an EGFR pharmDx™ kit (Dako) according to the manufacturer's instructions. Briefly, 4-μm paraffin-embedded tissue sections were deparaffinized, incubated with proteinase K solution, and treated with 3% H 2 O 2 to block endogenous peroxidase. They were then incubated with a mouse anti-human EGFR mAb (clone 2-18C9) at 4 °C overnight. They were washed with PBS and incubated with horseradish peroxidase (HRP)-conjugated polymers at room temperature for 30 minutes, followed by visualization with DAB (3, 3'-diaminobenzidine tetrahydrochloride). Finally, the slides were counterstained with hematoxylin.
Positive staining was evaluated and classified based on IHC scores (0, 1, 2 or 3)
according to the percentage of positive cells and staining intensity, as described by Chung and colleagues with a minor modification (23 Table S2 ).
Moreover, we analyzed the mutation status of KRAS (codons 61 and 146), NRAS (codons 12, 13 and 61), PIK3CA (codon 1047), and EGFR (exon 12 and exon 18-21) in these 10 cell lines and confirmed that there were no mutations in these genes. We then evaluated the inhibitory effect of cetuximab on cell growth in these 10 RAS, RAF wild-type CRC cell lines ( Figure 1 ).
The growth of CCK-81, LIM-1215, and HCA-7 cell lines was inhibited by more than 80% at 7 days after cetuximab treatment. Conversely, the growth of COLO320DM and PMF-ko14 was negligibly inhibited by cetuximab treatment. The remaining cell lines showed approximately 30% to 70% inhibition of cell growth at 7 days after cetuximab treatment. Thus, the growth-inhibitory effect of cetuximab varied even among RAS, RAF wild-type cell lines.
These results are consistent with clinical findings that the response to cetuximab differs even among cancers with no mutation in the EGFR signaling pathway. 
Decrease in cell surface
Cetuximab induces EGFR internalization and lysosomal degradation
To clarify the mechanism by which cell surface EGFRs decreased in cetuximab-sensitive CRC cells, we first compared the binding affinity of cetuximab to cell surface EGFR between cetuximab-sensitive and non-sensitive cell lines. However, we found no significant difference in the affinity of cetuximab for EGFR on the cell surface between cetuximab-sensitive cells and non-sensitive cells (Supplementary Figure S1) . It has been reported that EGFR ligands such as EGF and TGF-α stimulate receptor internalization, leading to intracellular degradation or recycling of EGFR to the cell surface (24) (25) (26) .
Cetuximab, an anti-EGFR mAb, also has been reported to induce EGFR internalization, similarly to the activating ligands (18) . To compare differences in EGFR trafficking after internalization, CCK-81 cells, which showed appreciable EGFR internalization with treatment, were incubated with the activating ligand TGF-α or cetuximab, and the chronological changes in EGFR numbers on the cell surface were examined. After stimulation with TGF-α, the EGFR number on the cell surface decreased by approximately 50% in 15 minutes, then close to 100% of the receptor recycled back to the cell surface, consistent with a previous report (25) . After stimulation with cetuximab, however, about 80% of EGFRs were internalized, and very little EGFR was recycled back to the cell surface ( Figure 3A) . Interestingly, when we observed cells up to 24 hours after cetuximab treatment, a majority of the internalized EGFRs were not recycled back to the cell surface over time (Supplementary Figure S2) . To extend these observations using a biotinylation approach, the cell surface proteins in CCK-81 cells treated with TGF-α or cetuximab were labeled with biotin, precipitated, and subjected to 20 Western blot analysis using anti-EGFR antibody. As shown in Figure 3B , 
Cetuximab-dependent EGFR internalization correlates with decreased MAP kinase signaling
We first observed the amount of internalized EGFR in CCK-81 (cetuximab-responsive) and Caco-2 (non-responsive) cell lines using a biotinylation-based EGFR internalization assay. As shown in Figure 4A , we confirmed EGFR internalization after treatment with cetuximab occurred more efficiently in CCK-81 cells than in Caco-2 cells. To determine whether a decrease in the number of EGFRs on the cell surface is associated with signal transduction downstream of EGFR, we investigated p-ERK and ERK expression in CCK-81 and Caco-2 cells by Western blotting after treatment with cetuximab ( Figure 4B ). In CCK-81 cells, which showed marked EGFR internalization, phosphorylation of ERK was 
EGFR degradation in CRC tissue is associated with the tumor response to anti-EGFR treatment
To assess the clinical relevance of the in vitro findings, we investigated changes in EGFR expression after anti-EGFR mAb treatment in cancer tissues from 13 CRC patients in association with response to the treatment. Figure 5A shows representative staining patterns of EGFR before and after treatment: i.e., marked decrease (Case 5, Figure 5A This report also supports our theory that the localization and trafficking of antibody-bound EGFR are different from those of ligand-bound EGFR; ligand-bound EGFR is destined predominantly for recycling but antibody-bound EGFR, predominantly for lysosomal degradation. These findings are quite consistent with the data showing that EGFR downregulation is significantly correlated with the efficacy of anti-EGFR antibody treatment.
Thus, our data suggest that EGFR trafficking and degradation after antibody-binding is a key mechanism of responsiveness to anti-EGFR antibody therapy.
Recently, early tumor shrinkage (ETS) and depth of response have received much attention as predictors of treatment outcomes for long-term survival (34, 35) . In particular, ETS has been achieved more frequently with treatment protocols that include anti-EGFR antibodies for RAS wild-type. The present study revealed that EGFR was rapidly downregulated in cetuximab-sensitive CRC cell lines after exposure to cetuximab, leading to strong inhibition of cell growth and enhanced apoptosis. This rapid EGFR downregulation is explained by efficient EGFR degradation in lysosomes without recycling to the cell surface.
When the 13 patients with mCRC enrolled in this study were divided into ETS and non-ETS groups, there was a significant difference in EGFR downregulation by IHC (Supplementary Table S3 ). In this context, our results may explain the clinical phenomenon of ETS following treatment with anti-EGFR antibodies: i.e., ETS is achieved by rapid EGFR downregulation and subsequent growth inhibition and augmentation of apoptosis. ADCC is proposed as one of the mechanisms of cetuximab anti-tumor activity. ADCC activity is reportedly correlated with the absolute number of EGFRs on the cell surface, irrespective of the presence of RAS mutation and RAF mutation (36) . Therefore, the correlation between the percentage decrease in the EGFR number, ADCC activity, and therapeutic effect is unclear in this study. In vivo experiments will be needed for a more detailed analysis. Western blot data by densitometry. Western blot data were scanned by densitometry and analyzed using Image J software. The p-ERK signal was normalized to the corresponding total ERK signal and then set to 100% for untreated controls. Error bars show mean ± SD.
P-values were determined using Student's t test. *p <0.001. C) Expression of PARP and cleaved PARP in CCK-81 or Caco-2 cells. The cells were treated with cetuximab (100 nM) or vehicle for 5 days, and Western blotting for PARP and cleaved PARP was performed. β-actin was used as a loading control. anti-EGFR antibody. The numbers of patients in the "no change", "moderate decrease", and "marked decrease" categories were compared between responder and non-responder groups using the chi-square test. 
